← Leaderboards
Arul M Chinnaiyan
University Of Michigan At Ann Arbor
$35,112,976
Attributed
$45,853,346
Total exposure
27
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$83,030,087 · 31
By mechanism
P50$36,649,565 · 15
UM1$12,776,087 · 2
U01$11,326,193 · 3
R35$6,389,118 · 1
R01$5,951,001 · 4
U2C$5,862,286 · 5
Top collaborators
- Ganesh S Palapattu11 shared
- Elisabeth Iljas Heath9 shared
- Kenneth J. Pienta8 shared
- Scott Roberts8 shared
- Mark A. Rubin6 shared
- David George Beer5 shared
- Jolanta Grembecka5 shared
- Alexey I Nesvizhskii5 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Martin G Sanda$22,920,886
- Jack E Dixon$15,595,348
- Bethany S Strunk$924,984
- Amber Joyce McCartney$60,812
- Scott A Tomlins$2,737,217
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateMalignant NeoplasmsProstateMichiganUniversitiesGene FusionCancer PatientProgramsResearch PersonnelBaseCommunitiesCollaborationsDiagnosisPathologyBioinformaticsValidationSamplingMutationSuccessMissionMolecularCohortEarly Detection Research NetworkUrine
Grant awards (125)
Michigan Prostate SPORE 2025-2030$2,303,511
P50 · FY2025 · CA · contact PI
Michigan-VUMC Biomarker Characterization Center$955,526
U2C · FY2025 · CA · contact PI
Administrative Core$427,245
U2C · FY2025 · CA · contact PI
Project 1 - Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in neuroendocrine prostate cancer$327,334
P50 · FY2025 · CA · contact PI
Administrative Core$290,050
P50 · FY2025 · CA · contact PI
Biomarker Developmental Laboratory$249,433
U2C · FY2025 · CA · contact PI
Michigan-VUMC Biomarker Characterization Center$907,751
U2C · FY2024 · CA · contact PI
Exploring Precision Oncology: From Gene Fusions to lncRNAs$882,218
R35 · FY2024 · CA · contact PI
Administrative Core$405,884
U2C · FY2024 · CA · contact PI
Biomarker Developmental Laboratory$236,962
U2C · FY2024 · CA · contact PI
Michigan Prostate SPORE$1,482,465
P50 · FY2023 · CA · contact PI
Michigan-VUMC Biomarker Characterization Center$936,416
U2C · FY2023 · CA · contact PI
Exploring Precision Oncology: From Gene Fusions to lncRNAs$910,078
R35 · FY2023 · CA · contact PI
Administrative Core$418,701
U2C · FY2023 · CA · contact PI
Admin-Core-001$297,550
P50 · FY2023 · CA · contact PI
Biomarker Developmental Laboratory$244,444
U2C · FY2023 · CA · contact PI
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12$230,649
P50 · FY2023 · CA · contact PI
Administration Core$162,694
P50 · FY2023 · CA · contact PI
Michigan Prostate SPORE$1,727,892
P50 · FY2022 · CA · contact PI
Exploring Precision Oncology: From Gene Fusions to lncRNAs$910,078
R35 · FY2022 · CA · contact PI
Michigan-VUMC Biomarker Characterization Center$680,576
U2C · FY2022 · CA · contact PI
Administration Core$416,517
P50 · FY2022 · CA · contact PI
Admin-Core-001$351,000
P50 · FY2022 · CA · contact PI
Michigan Prostate SPORE$351,000
P50 · FY2022 · CA · contact PI
Biomarker Developmental Laboratory$249,433
U2C · FY2022 · CA · contact PI
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12$188,052
P50 · FY2022 · CA · contact PI
Administrative Core$149,915
U2C · FY2022 · CA · contact PI
Michigan Prostate SPORE$1,727,891
P50 · FY2021 · CA · contact PI
Exploring Precision Oncology: From Gene Fusions to lncRNAs$928,651
R35 · FY2021 · CA · contact PI
Michigan Prostate SPORE$351,000
P50 · FY2021 · CA · contact PI
Administration Core$351,000
P50 · FY2021 · CA · contact PI
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer$234,675
U01 · FY2021 · CA · contact PI
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12$222,878
P50 · FY2021 · CA · contact PI
Administration Core$169,142
P50 · FY2021 · CA · contact PI
Michigan Prostate SPORE$1,725,106
P50 · FY2020 · CA · contact PI
Exploring Precision Oncology: From Gene Fusions to lncRNAs$928,651
R35 · FY2020 · CA · contact PI
University of Michigan Proteogenomics Data Analysis Center$768,426
U24 · FY2020 · CA
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer$574,716
U01 · FY2020 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$368,224
R01 · FY2020 · CA
Michigan Prostate SPORE$351,000
P50 · FY2020 · CA · contact PI
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12$269,895
P50 · FY2020 · CA · contact PI
Administration Core$205,336
P50 · FY2020 · CA · contact PI
Michigan Prostate SPORE$1,783,426
P50 · FY2019 · CA · contact PI
Exploring Precision Oncology: From Gene Fusions to lncRNAs$900,791
R35 · FY2019 · CA · contact PI
University of Michigan Proteogenomics Data Analysis Center$750,610
U24 · FY2019 · CA
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer$556,991
U01 · FY2019 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$362,030
R01 · FY2019 · CA
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12$277,748
P50 · FY2019 · CA · contact PI
Administration Core$215,011
P50 · FY2019 · CA · contact PI
SPORE in Prostate Cancer$2,300,000
P50 · FY2018 · CA · contact PI
Exploring Precision Oncology: From Gene Fusions to lncRNAs$928,651
R35 · FY2018 · CA · contact PI
University of Michigan Proteogenomics Data Analysis Center$894,121
U24 · FY2018 · CA
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer$806,986
U01 · FY2018 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$378,124
R01 · FY2018 · CA
A Precision Medicine Approach to Elucidate Mechanisms of Progression$340,768
P50 · FY2018 · CA · contact PI
Administration$290,164
P50 · FY2018 · CA · contact PI
SPORE in Prostate Cancer$2,380,000
P50 · FY2017 · CA · contact PI
University of Michigan Proteogenomics Data Analysis Center$831,340
U24 · FY2017 · CA
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer$573,018
U01 · FY2017 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$386,776
R01 · FY2017 · CA
A Precision Medicine Approach to Elucidate Mechanisms of Progression$327,989
P50 · FY2017 · CA · contact PI
Administration$277,387
P50 · FY2017 · CA · contact PI
SPORE in Prostate Cancer$2,161,999
P50 · FY2016 · CA · contact PI
Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers$1,980,271
UM1 · FY2016 · HG · contact PI
Sequencing, Analysis, and Interpretation of Sequencing$1,269,021
UM1 · FY2016 · HG · contact PI
University of Michigan Proteogenomics Data Analysis Center$831,340
U24 · FY2016 · CA
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer$572,443
U01 · FY2016 · CA · contact PI
Integrative molecular imaging and sequencing of prostate cancer$399,969
U01 · FY2016 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$392,750
R01 · FY2016 · CA
A Precision Medicine Approach to Elucidate Mechanisms of Progression$319,824
P50 · FY2016 · CA · contact PI
Administration$272,831
P50 · FY2016 · CA · contact PI
SPORE in Prostate Cancer$2,185,001
P50 · FY2015 · CA · contact PI
Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers$1,930,815
UM1 · FY2015 · HG · contact PI
Sequencing, Analysis, and Interpretation of Sequencing$1,242,163
UM1 · FY2015 · HG · contact PI
Integrative molecular imaging and sequencing of prostate cancer$408,401
U01 · FY2015 · CA · contact PI
A Precision Medicine Approach to Elucidate Mechanisms of Progression$318,833
P50 · FY2015 · CA · contact PI
Identification and Characterization of Gene Fusions in Lung Adenocarcinoma$287,037
R01 · FY2015 · CA
Administration$276,384
P50 · FY2015 · CA · contact PI
A Systems Biology Approach to the Development of Cancer Biomarkers$163,530
U01 · FY2015 · CA · contact PI
SPORE in Prostate Cancer$2,162,000
P50 · FY2014 · CA · contact PI
Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers$1,940,764
UM1 · FY2014 · HG · contact PI
Sequencing, Analysis, and Interpretation of Sequencing$1,202,393
UM1 · FY2014 · HG · contact PI
A Systems Biology Approach to the Development of Cancer Biomarkers$614,261
U01 · FY2014 · CA · contact PI
Integrative molecular imaging and sequencing of prostate cancer$416,880
U01 · FY2014 · CA · contact PI
A Precision Medicine Approach to Elucidate Mechanisms of Progression$309,509
P50 · FY2014 · CA · contact PI
Identification and Characterization of Gene Fusions in Lung Adenocarcinoma$278,426
R01 · FY2014 · CA
Administration$274,357
P50 · FY2014 · CA · contact PI
Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers$1,992,227
UM1 · FY2013 · HG · contact PI
Sequencing, Analysis, and Interpretation of Sequencing$1,218,433
UM1 · FY2013 · HG · contact PI
A Systems Biology Approach to the Development of Cancer Biomarkers$634,323
U01 · FY2013 · CA · contact PI
SPORE in Prostate Cancer$560,104
P50 · FY2013 · CA · contact PI
Identification and Characterization of Gene Fusions in Lung Adenocarcinoma$269,423
R01 · FY2013 · CA
Molecuar Sub-typing of Prostate Cancer Based on Recurrent Gene Fusions$233,850
R01 · FY2013 · CA · contact PI
SPORE in Prostate Cancer$2,300,000
P50 · FY2012 · CA · contact PI
A Systems Biology Approach to the Development of Cancer Biomarkers$685,047
U01 · FY2012 · CA · contact PI
Tissue/Informatics Core$490,416
P50 · FY2012 · CA · contact PI
Identification and Characterization of Gene Fusions in Lung Adenocarcinoma$286,245
R01 · FY2012 · CA
Molecular Sub-Typing of Prostate Cancer Based on Recurrent Gene Fusions$285,802
P50 · FY2012 · CA · contact PI
Molecuar Sub-typing of Prostate Cancer Based on Recurrent Gene Fusions$248,776
R01 · FY2012 · CA · contact PI
A Systems Biology Approach to the Development of Cancer Biomarkers$695,128
U01 · FY2011 · CA · contact PI
Tissue/Informatics Core$464,174
P50 · FY2011 · CA · contact PI
Identification and Characterization of Gene Fusions in Lung Adenocarcinoma$284,052
R01 · FY2011 · CA
Molecular Sub-Typing of Prostate Cancer Based on Recurrent Gene Fusions$270,783
P50 · FY2011 · CA · contact PI
Molecuar Sub-typing of Prostate Cancer Based on Recurrent Gene Fusions$248,776
R01 · FY2011 · CA · contact PI
A Systems Biology Approach to the Development of Cancer Biomarkers$703,683
U01 · FY2010 · CA · contact PI
Tissue/Informatics Core$487,605
P50 · FY2010 · CA · contact PI
Molecular Sub-Typing of Prostate Cancer Based on Recurrent Gene Fusions$284,755
P50 · FY2010 · CA · contact PI
Molecuar Sub-typing of Prostate Cancer Based on Recurrent Gene Fusions$256,470
R01 · FY2010 · CA · contact PI
Tissue/Informatics Core$483,978
P50 · FY2009 · CA · contact PI
Epitomic Biomarkers of Prostate Cancer$449,756
U01 · FY2009 · CA · contact PI
Molecular Sub-Typing of Prostate Cancer Based on Recurrent Gene Fusions$282,938
P50 · FY2009 · CA · contact PI
Molecuar Sub-typing of Prostate Cancer Based on Recurrent Gene Fusions$256,470
R01 · FY2009 · CA · contact PI
Epitomic Biomarkers of Prostate Cancer$581,526
U01 · FY2008 · CA · contact PI
Tissue/Informatics Core$481,996
P50 · FY2008 · CA · contact PI
Molecular Sub-Typing of Prostate Cancer Based on Recurrent Gene Fusions$281,821
P50 · FY2008 · CA · contact PI
Epitomic Biomarkers of Prostate Cancer$566,449
U01 · FY2007 · CA · contact PI
The Role of Polycomb Group Proteins in Prostate Cancer$75,988
R01 · FY2007 · CA · contact PI
Epitomic Biomarkers of Prostate Cancer$568,278
U01 · FY2006 · CA · contact PI
The Role of Polycomb Group Proteins in Prostate Cancer$262,464
R01 · FY2006 · CA · contact PI
Epitomic Biomarkers of Prostate Cancer$662,637
U01 · FY2005 · CA
The Role of Polycomb Group Proteins in Prostate Cancer$268,780
R01 · FY2005 · CA
Epitomic Biomarkers of Prostate Cancer$457,496
U01 · FY2004 · CA
The Role of Polycomb Group Proteins in Prostate Cancer$268,780
R01 · FY2004 · CA
The Role of Polycomb Group Proteins in Prostate Cancer$268,780
R01 · FY2003 · CA
The Role of Polycomb Group Proteins in Prostate Cancer$268,780
R01 · FY2002 · CA